Warnex Launches Test for Influenza A H1N1 Virus Mutation Associated With Resistance to Tamiflu®
News Sep 01, 2009
Warnex Inc. has announced that its Medical Laboratories division has launched a test for the detection of a mutation of the pandemic influenza A H1N1 virus, which is associated with resistance to Tamiflu®, a drug used for the treatment and prevention of the flu.
The test specifically detects the H275Y mutation of the neuraminidase gene, which has been shown to cause resistance to Tamiflu.
"We have begun to see cases of Tamiflu resistance of the A H1N1 virus on a global scale, and recently also here in Quebec," said Mark Busgang, President and CEO of Warnex.
"We are offering this test for the identification of a Tamiflu-resistant strain in addition to our test for the rapid detection of the H1N1 flu virus, demonstrating the commitment of our Medical Laboratories division to serve as a reference laboratory and make available such highly specialized medical tests to the Canadian healthcare sector."
y conjuring the spell “Lumos!” wizards in the mythical world of Harry Potter could light up the tip of their magic wands and illuminate their surroundings. So, too, does LumosVar, a computer program that “lights up” cancer-causing genetic Var-ients, or mutations, illuminating how physicians might best treat their patients.READ MORE
By leveraging an organ-on-a-chip model and a bioreactor, four human gut metabolites have been identified that can help explain the enhanced sensitivity of the human colon towards enterohemorrhagic E. coli, which is responsible for more than 100,000 infections per year in the USA alone.READ MORE